---

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

FORM 10-QSB

(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period endedJune 30, 2008

[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF
THE EXCHANGE ACT

For the transition period from _______________ to
_______________

Commission file number: **000-52885**

PURE PHARMACEUTICALS CORPORATION(Exact name of small business issuer as specified in its
charter)

|NEVADA                                                               | 45-0476087                       
|-------------------------------------------------------------------- | ---------------------------------
|(State or other jurisdiction of incorporation or
      organization) | (IRS Employer Identification No.)

P.O. BOX 55, 1594 STONE MILL PARK, BELLONA, NY, 14415(Address of principal executive offices)

(315) 849-2822(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X]   No [   ]

Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes [X]   No
[   ]

APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's
classes of common equity, as of the latest practicable date: At June 30,
2008, there were 12,600,000 shares of the registrant's Common Stock outstanding.

Transitional Small Business Disclosure Format (Check one): Yes
[   ]   No [X]

Persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB control number.

---

PART I  FINANCIAL INFORMATION

ITEM
1.              
FINANCIAL STATEMENTS



PURE PHARMACEUTICALS CORPORATION(A Development Stage Company)

FINANCIAL STATEMENTS

JUNE 30, 2008









|BALANCE
      SHEETS                   
|---------------------------------------
|                                       
|STATEMENTS
      OF OPERATIONS         
|                                       
|STATEMENTS
      OF CASH FLOWS         
|                                       
|NOTES
      TO THE FINANCIAL STATEMENTS

---

PURE PHARMACEUTICAL CORPORATION(A Development
Stage Company)

BALANCE SHEETS

(Unaudited)

|                                                       |  |               |   |  | September 30, |  
|------------------------------------------------------ |  | ------------- | - |  | ------------- | -
|                                                       |  | June 30, 2008 |   |  | 2007          |  
|                                                       |  | - $
      -   |   |  | - $
      -   |  
|                                                       |  |               |   |  |               |  
|ASSETS                                                 |  |               |   |  |               |  
|                                                       |  |               |   |  |               |  
|Current                                                |  |               |   |  |               |  
|Cash                                                   |  | 22,574        |   |  | 28,906        |  
|Inventory                                              |  | 5,130         |   |  | 5,130         |  
|                                                       |  | 27,704        |   |  | 34,036        |  
|                                                       |  |               |   |  |               |  
|LIABILITIES                                            |  |               |   |  |               |  
|                                                       |  |               |   |  |               |  
|Current                                                |  |               |   |  |               |  
|Accounts payable and accrued liabilities               |  | 42,018        |   |  | 48,508        |  
|Note payable (Note 2)                                  |  | 40,000        |   |  | -             |  
|                                                       |  | 82,018        |   |  | 48,508        |  
|                                                       |  |               |   |  |               |  
|STOCKHOLDERS DEFICIT                                  |  |               |   |  |               |  
|Common stock:                                          |  |               |   |  |               |  
|Authorized:                                            |  |               |   |  |               |  
|100,000,000 common shares,                             |  |               |   |  |               |  
|with a par value of $0.001                             |  |               |   |  |               |  
|Issued and Outstanding:                                |  |               |   |  |               |  
|12,600,000 common shares (2007
       12,600,000)     |  | 12,600        |   |  | 12,600        |  
|Additional paid-in capital                             |  | 159,400       |   |  | 152,200       |  
|Accumulated comprehensive loss                         |  | 256           |   |  | 600           |  
|Deficit
      accumulated during the development stage |  | (226,570      | ) |  | (179,872      | )
|                                                       |  | (54,314       | ) |  | (14,472       | )
|                                                       |  | 27,704        |   |  | 34,036        |  

The accompanying notes are an integral part of these financial
statements.

---

PURE PHARMACEUTICAL CORPORATION(A Development
Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

CumulativefromThree months
    
    
    
    
    
    
    
    
    September 24,Three months
    
    
    ended
    
    
    Nine
    
    
    Nine months
    
    
      **2004(Date of**ended
    
    
    June 30,
    
    
    months ended
    
    
    ended
    
    
    inception) toJune 30, 2008
    
    
    2007
    
    
    June 30, 2008
    
    
    June 30, 2007
    
    
    June 30, 2008-
      $ -
    
    
    -
      $ -
    
    
    -
      $ -
    
    
    -
      $ -
    
    
    -
      $ -Revenue
    
    -
    
    
    -
    
    
    -
    
    
    9,088
    
    
    12,088Cost of sales
    
    -
    
    
    -
    
    
    -
    
    
    7,270
    
    
    9,670-
    
    
    -
    
    
    -
    
    
    1,818
    
    
    2,418ExpensesFinancing fees
    
    -
    
    
    -
    
    
    -
    
    
    -
    
    
    5,600General andadministrative
    
    9,703
    
    
    12,860
    
    
    46,698
    
    
    21,913
    
    
    223,388Net loss
    
    (9,703
    )
    
    (12,860
    )
    
    (46,698
    )
    
    (20,095
    )
    
    (226,570
    )Net loss per share -basic and diluted
    
    (0.00
    )
    
    (0.00
    )
    
    (0.00
    )
    
    (0.00
    )Weighted averagenumber of commonshares outstanding
    
    12,600,000
    
    
    12,600,000
    
    
    12,600,000
    
    
    12,600,000


The accompanying notes are an integral part of these
financial****statements.

---

PURE PHARMACEUTICAL CORPORATION(A Development
Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

|                                                |  |               |   |  |             |   |  | Period from   |  
|----------------------------------------------- |  | ------------- | - |  | ----------- | - |  | ------------- | -
|                                                |  |               |   |  | Nine months |   |  | September 24, |  
|                                                |  | Nine months   |   |  | ended       |   |  | 2004 (Date of |  
|                                                |  | ended         |   |  | June 30,    |   |  | inception) to |  
|                                                |  | June 30, 2008 |   |  | 2007        |   |  | June 30, 2008 |  
|                                                |  | -
      $ -   |   |  | -
      $ - |   |  | -
      $ -   |  
|                                                |  |               |   |  |             |   |  |               |  
|Cash Flows From Operating Activities            |  |               |   |  |             |   |  |               |  
|Net loss                                        |  | (46,698       | ) |  | (20,095     | ) |  | (226,570      | )
|Non-cash items:                                 |  |               |   |  |             |   |  |               |  
|Non-cash administrative expenses                |  | 7,200         |   |  | 7,200       |   |  | 36,000        |  
|Foreign exchange                                |  | (344          | ) |  | (7          | ) |  | 256           |  
|Net change in non-cash working capital items:   |  |               |   |  |             |   |  |               |  
|Inventory                                       |  | -             |   |  | 7,270       |   |  | (5,130        | )
|Accounts payable and accrued liabilities        |  | (6,490        | ) |  | (12,715     | ) |  | 42,018        |  
|Net cash used in operations                     |  | (46,332       | ) |  | (18,347     | ) |  | (153,426      | )
|                                                |  |               |   |  |             |   |  |               |  
|Cash Flows From Financing Activities            |  |               |   |  |             |   |  |               |  
|Capital stock issued                            |  | -             |   |  | 2,000       |   |  | 136,000       |  
|Note payable                                    |  | 40,000        |   |  | -           |   |  | 40,000        |  
|Net cash
      provided by financing activities |  | 40,000        |   |  | 2,000       |   |  | 176,000       |  
|                                                |  |               |   |  |             |   |  |               |  
|Increase (decrease) in cash                     |  | (6,332        | ) |  | (16,347     | ) |  | 22,574        |  
|                                                |  |               |   |  |             |   |  |               |  
|Cash,
      beginning                           |  | 28,906        |   |  | 54,124      |   |  | -             |  
|Cash, ending                                    |  | 22,574        |   |  | 37,777      |   |  | 22,574        |  
|                                                |  |               |   |  |             |   |  |               |  
|Supplementary Cash Flow Information:            |  |               |   |  |             |   |  |               |  
|Cash paid for:                                  |  |               |   |  |             |   |  |               |  
|Interest                                        |  | -             |   |  | -           |   |  | -             |  
|Income taxes                                    |  | -             |   |  | -           |   |  | -             |  

The accompanying notes are an integral part of these financial
statements.

---

PURE PHARMACEUTICAL CORPORATION(A Development
Stage Company)

NOTES TO THE FINANCIAL STATEMENTS

JUNE 30, 2008 (Unaudited)

|1.     | BASIS OF PRESENTATION                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
|------ | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|       | Unaudited Interim Financial Statements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|       | The accompanying unaudited interim financial statements
      have been prepared in accordance with generally accepted accounting
      principles for interim financial statements and in accordance with the
      rules and regulations of the Securities and Exchange Commission. They may
      not include all information and footnotes required by generally accepted
      accounting principles for complete financial statements. However, except
      as disclosed herein, there has been no material changes in the information
      disclosed in the notes to the financial statements for the year ended
      September 30, 2007 included in the Companys Form 10-KSB filed with the
      Securities and Exchange Commission. The unaudited interim financial
      statements should be read in conjunction with those financial statements
      included in the Form 10-KSB. In the opinion of Management, all adjustments
      considered necessary for a fair presentation, consisting solely of normal
      recurring adjustments, have been made. Operating results for the nine
      months ended June 30, 2008 are not necessarily indicative of the results
  that may be expected for the year ending September 30, 2008.
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|**2.** | **NOTE PAYABLE**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
|       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
|       | The balance is owing to a non-related party in the amount of $40,000 as at June 30, 2008 (Nil – September 30, 2007).  The full amount is unsecured, bears an interest rate of 5% per annum and due in May 2009.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

---

**ITEM
2.** **MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

Forward Looking Statements

In addition to historical information, the following discussion
and other parts of this document may contain forward-looking statements. These
statements relate to future events or our future financial performance. In some
cases, you can identify forward-looking statements by terminology such as "may,"
"will," "should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential," or "continue," the negative of such terms or other
comparable terminology. These statements are only predictions. The events
described in forward looking statements we make in this Form 10-QSB may not
occur. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements. We caution you that these
statements are not guarantees of future performance or events and are subject to
a number of uncertainties risks and other influences, many of which are beyond
our control that may influence the accuracy of the statements and the
projections upon which the statements are based. Moreover, neither we nor any
other person assume responsibility for the accuracy and completeness of the
forward-looking statements. Except as may be required by law, we undertake no
obligation to publicly update any of the forward-looking statements after the
date of this report to conform such statements to actual results or to changes
in our expectations.

Actual results could differ materially from those anticipated
by such forward-looking statements. The following discussion should be read in
conjunction with the financial statements as well as other financial information
appearing elsewhere in this document. Readers are also urged to carefully review
and consider the various disclosures made by us which attempt to advise
interested parties of the factors which affect our business.

Our Business

The Company was formed in order to seek business opportunities
in the area of expertise of the Company's principal stockholder, Mr. Roger
Gordon, being biological and/or medical products for animal use. The Company
principally operated in the field of generic animal health and nutrition
products, specifically medicated feed additives (MFAs). MFAs are used
preventively and therapeutically in animal feed to prevent disease and foster
growth in livestock. In North America, 90% of all feed to animals contain MFAs.
Our intended customers operate in the poultry, swine and cattle markets. The
Company has historically focused its efforts on generic MFAs, as they have come
off patent, therefore making them more economical to register with requisite
regulators in the United States and Canada, with a view to bringing the products
to market.

The Company continued to market a related-party owned MFA,
Oxytetracycline, and was in the exploratory phase of identifying generic MFAs
that it intended to test and register with regulatory authorities with a view to
being granted a DIN or similar authorization to market such MFAs in North
America (henceforth, the identification process). As market dynamics have
undergone significant systemic changes over the past three years with the
emergence of avian flu and the attendant fall in poultry consumption worldwide,
management has had to conduct the identification process with due deliberation.
Furthermore, with the prices of feed, particularly maize, at record high prices,
our intended customers have been hesitant to add to their expenses.

The Company's activities to date have been primarily
organizational in nature and as a result the Company must be considered to be in
its developmental stage. The Company relies solely on the efforts of its
management and director and has no employees, owns few business assets,
technology or real estate

---

and since inception has been primarily involved in developing
its business plan, preliminarily identifying generic MFAs for registration, and
raising initial capital.

In the last quarter, management determined to refocus, assess
and identify alternative business strategies due to prolonged high prices of
maize and other inputs and other general economic conditions effecting the
business of the Company.

Recent Developments

Sales have decreased year over year due to the increasing
prices of maize. As a result of the prolonged high prices of inputs and other
general conditions effecting the business of the Company, management determined,
in the prior quarter, to refocus, assess and identify alternative business
strategies. In July, 2008, the Company was quoted on the OTC Bulletin Board
under the symbol PCMS.

Results of Operations

Results of Operations for the Period ended June 30, 2008

We did not earn any revenues in the three months ended June 30,
2008. We incurred operating expenses in the amount of $9,703 for the three
months ended June 30, 2008. Our net loss for the three months ended June 30,
2008 was $9,703. As at June 30, 2008 we had cash of $22,574. Our losses stem
from the payment of professional fees and the inability to generate revenue.

Sales and marketing of the companys Oxytetracyline and the
process of the company pursuing opportunties in the generic MFAs areas continue
to be very difficult this quarter. Due to an acute worldwide increase in the
price of key ingredients; corn and soybeans; the ability for producers to absorb
upward pricing pressure is severely challenged. Corn prices have surged five
fold in the last 24 months to $750 USD per brushel to its highest all time
recorded price1. Corn prices continue to break historic records.
Management and analysis believe the competition for corn, once viewed as a
commodity and now viewed as a matter of national security for countries, is here
to stay. The use of corn for the production of ethanol and the agricultural
policies of leading petroleum usage countries continue to exert price and demand
pressures on the market2.

Due to the prolonged high prices of inputs, an upward cycle
which has lasted for two years, and general conditions which are effecting the
business of the company; management has determined to refocus, assess, and
identify alternative business strategies.

Results of Operations from the Fiscal Year ended September
30, 2007

In the fiscal year ended September 30, 2007, we had net revenue
in the amount of $12,088, operating expenses in the amount of $64,886 and our
net loss was $62,468. As at September 30, 2007 we had cash of $28,906 and
working capital of $34,036.

As a result of its activities in late fiscal 2006, the Company
located suitable clients willing to purchase the MFA and was able to book its
first sale in the first quarter of fiscal 2007 for $5,104. During the second
quarter of fiscal 2007, the Company booked a sale in the amount of $3,984. In
the third quarter, the Company was unable to make any sales. In the fourth
quarter, the Company booked a sale of $3,000. Management believes that its
inability to generate greater sales is attributable to the high price of maize

__________________________________________________1
http://futures.tradingcharts.com/chart/CN/M
2 http://www.financialpost.com/story.html?id=311350

---

which is one of the largest cost components of feed. Maize
prices have increased dramatically in the last 12 months from its historic
averages. There are many factors driving the price of maize higher, including
its use as an emerging fuel (ethanol). This significant jump in prices have
forced upward "at the gate" prices for poultry in cities such as Toronto where
from the period of January to June 2007, prices for poultry had increased 11.6%
from $1.16 to $1.29/kilogram. Management believes that until retail customers
are willing to pay more, animal producers are going to continue a cautious
approach towards shouldering additional "cost risk"

To broaden our distribution network, the Company set up a
website, www.purepharmacorp.com, to complement sales efforts.

Results of Operations for the Period ended September 30,
2006

We did not earn any revenue from the period from our inception
on September 24, 2004 to September 30, 2006. We incurred operating expenses in
the amount of $52,963 for the year ended September 30, 2006. These operating
expenses were comprised primarily of $38,322 for professional fees and $14,641
in office and general expenses. Our net loss for the year ended September 30,
2006 was $52,963. As at September 30, 2006 we had cash of $54,124 and working
capital of $35,692.

Since the acquisition of the license (CAS: 6153-64-6) to market
Oxytetracycline in Canada, in the third quarter of fiscal 2006 the Company was
able to secure manufacturing in the Far East with Jiangxi Pharmaceutical Factory
in China. After running tests, the factory demonstrated the efficacy of the
aforementioned MFA and the Company placed its first order and received
deliveries from its supply chain in the fourth quarter (July to September) of
fiscal 2006.

Results of Operations for Period Ending September 30, 2005
(as restated) from Inception

We did not earn any revenue from the period from our inception
on September 24, 2004 to September 30, 2005. We incurred operating expenses in
the amount of $64,441 for the year ended September 30, 2005. These operating
expenses were comprised primarily of $39,463 for professional fees and, $24,978
in office and general expenses. Our net loss for the year ended September 30,
2005 was $64,441. As at September 30, 2005, we had cash of $89,177 and working
capital of $72,600.

Liquidity and Capital Resources

Our cash reserves are not sufficient to meet our funding needs
beyond the next nine-month period. To this effect, we have raised $40,000 USD in
outside capital in terms of a loan. Management believes
even with this capital injection, we will need to seek additional funding in the
near future. We currently do not have a specific plan for obtaining such
funding, however, we anticipate that any additional funding will be in the form
of equity financing from the sale of our common stock and/or loans (interest or
convertible). We currently do not have any arrangements in place for any future
equity financing. We may also seek to obtain short-term loans from our
directors, although no such arrangements have as yet been made. There can be no
assurance that we will able to raise sufficient funding from the sale of our
common stock or through director loans to meet our funding needs after the next
six months.

The Independent Auditor's Report to our audited financial
statements for the period ended September 30, 2007 indicated that there are a
number of factors that raise substantial doubt about our ability to continue as
a going concern. Such factors identified in the report include that we need to
generate profitable

---

operations and are in need of obtaining adequate financing. For
these and other related reasons our auditors believe that there is substantial
doubt that we will be able to continue as a going concern.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on the
small business issuer's financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.

**ITEM
3.** **CONTROLS
AND PROCEDURES**

Evaluation of Disclosure Controls and Procedures. The
Company's Management under the supervision and with the participation of the
Principal Executive Officer and the Principal Financial Officer are responsible
for establishing and maintaining "disclosure controls and procedures" (as
defined in the Exchange Act) for the Company. Based on their evaluation of the
Company's disclosure controls and procedures as of June 30, 2008, the Company's
Management has concluded that the Company's disclosure controls and procedures
were effective to ensure that the information required to be disclosed by the
Company under the Exchange Act was recorded, processed, summarized and reported
within the time periods specified in the Exchange Act and accumulated and
communicated to the Company's Management, including the Principal Executive
Officer and the Principal Financial Officer, to allow timely decisions regarding
required disclosure.

Changes in Internal Control over Financial Reporting.During the fiscal quarter ending June 30, 2008, there were no changes in the
Company's internal control over financial reporting during the period covered by
this report that have materially affected, or are reasonably likely to
materially affect, the Company's internal control over financial reporting.

Limitations on the Effectiveness of Controls.A control
system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met.
Because of the inherent limitations in all control systems, no evaluation of
controls can provide absolute assurance that all control issues, if any, within
a company have been detected. The Company's disclosure controls and procedures
are designed to provide reasonable assurance of achieving their objectives, and
the Principal Executive Officer and the Principal Financial Officer have
concluded that these controls and procedures are effective at the "reasonable
assurance" level.

ITEM 3A (T).       
CONTROLS AND PROCEDURES

The Company's management is responsible for establishing and
maintaining adequate internal control over financial reporting. Our internal
control over financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted
accounting principles.

Our internal control over financial reporting includes those
policies and procedures that:

- Pertain to the maintenance of records that, in reasonable detail,
  accurately and fairly reflect the transactions and dispositions of the assets
  of the Company;
- Provide reasonable assurance that transactions are recorded as necessary to
  permit preparation of financial statements in accordance with generally
  accepted accounting principles, and that

---

- Provide reasonable assurance regarding prevention or timely detection of
    unauthorized acquisition, use or disposition of assets that could have a material
    effect on the financial statements.

As required by Rule 13a-15 and 15d-15 under the Securities and
Exchange Act of 1934, Management assessed the effectiveness of the Companys
internal control over financial reporting as of June 30, 2008. Based on this
assessment, the Company's management has concluded that the Company maintained
effective internal control over financial reporting as of June 30, 2008, the end
of the period covered by this quarterly report.

This quarterly report does not include an attestation report of
the company's registered public accounting firm regarding internal control over
financial reporting. Management's report was not subject to attestation by the
company's registered public accounting firm pursuant to temporary rules of the
Securities and Exchange Commission ("SEC") that permit the Company to provide
only management's report in this quarterly report.

Changes in Internal Control over Financial Reporting.Management has evaluated whether any changes in our internal control over
financial reporting that occurred during our last fiscal quarter have materially
effected, or reasonably likely to materially effect our internal control over
financial reporting. Based on the evaluation we conducted, management has
concluded that during the fiscal quarter ending June 30, 2008, there were no
changes in the Company's internal control over financial reporting during the
period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Company's internal control over financial
reporting.

A control system, no matter how well conceived and operated,
can provide only reasonable, not absolute, assurance that the objectives of the
control system are met. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all
control issues, if any, within a company have been detected. The Company's
disclosure controls and procedures are designed to provide reasonable assurance
of achieving their objectives, and the Principal Executive Officer and the
Principal Financial Officer have concluded that these controls and procedures
are effective at the "reasonable assurance" level.

PART II  OTHER INFORMATION

**ITEM
1.** **LEGAL
PROCEEDINGS.**

We are not currently a party to any legal proceedings.

**ITEM
2.** **UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

None.

**ITEM
3.** **DEFAULTS UPON SENIOR SECURITIES**

None.

---

**ITEM
4.** **SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS**

No matters have been submitted to our security holders for a
vote, through the solicitation of proxies or otherwise, during the quarterly
period ended June 30, 2008.

**ITEM
5.** **OTHER
INFORMATION**

None.

**ITEM
6.** **EXHIBITS.**

|31.1 | Certification of Principal
        Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of
        2002.
|---- | -----------------------------------------------------------------------------------------------------------------------
|     |                                                                                                                        
|31.2 | Certification of Principal
        Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of
        2002.
|     |                                                                                                                        
|32.1 | Certification of Principal
        Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of
        2002.
|     |                                                                                                                        
|32.2 | Certification of Principal
        Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of
        2002.

---

SIGNATURES

In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

|                           |     | PURE PHARMACEUTICALS CORPORATION                         
|-------------------------- | --- | ---------------------------------------------------------
|                           |     | (Registrant)                                             
|                           |     |                                                          
|                           |     |                                                          
|Date:August 18,
      2008 | By: | */s/ Roger Gordon*                                       
|                           |     | Roger Gordon                                             
|                           |     | President, Principal Executive Officer and
      Director
|                           |     |                                                          
|                           |     |                                                          
|                           |     |                                                          
|Date:August 18,
      2008 | By: | /s/ Charlie Lee                                          
|                           |     | Charlie Lee                                              
|                           |     | Secretary and Principal Accounting Officer               

---